An experimental drug is showing potential in treating Type 2 diabetes. Tests show the new drug, dapagliflozin, significantly reduced blood sugar in patients with advanced Type 2 diabetes.
The drug lead to statistically significant weight loss and a slight reduction in needed insulin dose, according to data presented at the American Diabetes Association scientific meeting in Orlando on Saturday.
An experimental drug from a promising new class of medicines being developed by Bristol-Myers Squibb Co (BMY.N) and AstraZeneca PLC (AZN.L) significantly reduced blood sugar in patients with advanced Type 2 diabetes in a late-stage clinical trial.
The drug, dapagliflozin, also led to statistically significant weight loss and a slight reduction in needed insulin dose, according to data presented at the American Diabetes Association scientific meeting in Orlando on Saturday.
Dapagliflozin belongs to a new class of oral Type 2 diabetes treatments called sodium-glucose transporter-2 inhibitors. Blocking the SGLT2 protein significantly increases the amount of glucose excreted in the urine that would otherwise be reabsorbed into the blood after passing through the kidneys.
Researchers believe SGLT2 inhibitors will prove beneficial across the spectrum of the disease.